GSK announces data from the ZOSTER-049 long-term phase III trial of Shingrix

GSK announced positive data from the ZOSTER-049 long-term follow-up phase III trial which followed participants for up to approximately 11 years following initial vaccination with Shingrix. The final trial data demonstrate that RZV maintains efficacy against shingles for more than a decade in adults over 50. The data will be presented at ESCMID Global, European Society of Clinical Microbiology and Infectious Diseases, 2024, formerly known as ECCMID in Barcelona, Spain. The results from ZOSTER-049, an extension from two phase III clinical trials in adults aged 50 and over, include: 79.7% vaccine efficacy in adults aged greater than or equal to50 cumulatively within the period from year six to year 11 after vaccination; 82.0% VE in adults greater than or equal to50 at year 11, showing VE remains high in each year after vaccination; 73.1% VE in adults aged greater than or equal to70 cumulatively from six to 11 years after vaccination showing high VE rates across all age groups. Phil Dormitzer, Senior Vice President, Head of Vaccines R&D, said: “These data go far beyond the typical long-term follow-up period for a trial, tracking the efficacy of vaccination for some participants as they aged into their 70s, 80s and 90s. With the vaccine now included in many national immunisation programmes around the world, these data add to the body of evidence on the extended long-term protection against shingles and provide further confidence to inform public immunisation strategies.”